Tobacco smoking leads to extensive genome-wide changes in DNA methylation.
Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, Weidinger S, Lattka E, Adamski J, Peters A, Strauch K, Waldenberger M, Illig T. · 2013
Read Tobacco smoking leads to extensive genome-wide changes in DNA methylation. by Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, Weidinger S, Lattka E, Adamski J, Peters A, Strauch K, Waldenberger M, Illig T. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3656907.txt.
Introduction
Smoking leaves marks on DNA that fade after quitting, Zeilinger and a large team report in a 2013 PLoS ONE study. The marks are chemical tags, called methylation in the text, that can switch genes up or down. The team scanned tags across the genome in blood from 1,793 people in a German population panel, sorting current, former and never smokers. A second panel of 479 people served as a check.
Tag levels differed widely between the groups at many sites. The strongest change sat in a gene called AHRR, where smokers showed a drop of 24.40 percent at one site, hinting the tag steers that gene's work. In former smokers, tag levels sat close to never smokers, with the gap set by years since quitting and past dose. Smoking's reach is broad, but the marks can recover once the habit ends.
Catalog record
| CREATOR | Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, Weidinger S, Lattka E, Adamski J, Peters A, Strauch K, Waldenberger M, Illig T. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Tobacco Smoking Leads to Extensive Genome-Wide Changes in DNA Methylation By Sonja Zeilinger, Brigitte Kühnel, Norman Klopp, Hansjörg Baurecht, Anja Kleinschmidt, Christian Gieger, Stephan Weidinger, Eva Lattka, Jerzy Adamski, Annette Peters, Konstantin Strauch, Melanie Waldenberger Published in: PLoS ONE DOI: 10.1371/journal.pone.0063812 ABSTRACT Environmental factors such as tobacco smoking may have long-lasting effects on DNA methylation patterns, which might lead to changes in gene expression and in a broader context to the development or progression of various diseases. We conducted an epigenome-wide association study (EWAs) comparing current, former and never smokers from 1793 participants of the population-based KORA F4 panel, with replication in 479 participants from the KORA F3 panel, carried out by the 450K BeadChip with genomic DNA obtained from whole blood. We observed wide-spread differences in the degree of site-specific methylation (with p-values ranging from 9.31E-08 to 2.54E-182) as a function of tobacco smoking in each of the 22 autosomes, with the percent of variance explained by smoking ranging from 1.31 to 41.02. Depending on cessation time and pack-years, methylation levels in former smokers were found to be close to the ones seen in never smokers. In addition, methylation-specific protein binding patterns were observed for cg05575921 within AHRR, which had the highest level of detectable changes in DNA methylation associated with tobacco smoking (–24.40% methylation; p = 2.54E-182), suggesting a regulatory role for gene expression. The results of our study confirm the broad effect of tobacco smoking on the human organism, but also show that quitting tobacco smoking presumably allows regaining the DNA methylation state of never smokers. INTRODUCTION Epigenetic changes have been causally related to a variety of disease conditions including monogenic and complex multifactorial diseases [1]. The establishment and maintenance of epigenetic modifications, such as DNA methylation, can be modulated by environmental factors [2]–[4]. Tobacco smoking is a leading cause of disease and premature death worldwide [5]–[7]. The complex, dynamic and reactive mixture of an estimated 7,000 chemicals affects every organ system in the body and causes a wide spectrum of cardiovascular and chronic obstructive pulmonary diseases as well as various types of cancer, in particular lung cancer, through mechanisms that include DNA damage, inflammation, and oxidative stress [2], [3], [8], [9]. So far, it is insufficiently known how these mechanisms are triggered by tobacco smoking, but an association with altered DNA methylation patterns has been shown for a number of single genes, mostly cancer-related, and in genome-wide methylation studies [10]–[15]. These studies on tobacco smoking were relatively limited regarding the density of CpG site coverage and/or the number of samples analyzed. Although a few studies have already been carried out with the Illumina 27K BeadChip [10], [15], this array is limited by the fact that it only targets CpG sites located within the proximal promoter region of transcription start sites, with a focus on loci implicated in cancer. Until now, three studies concerning tobacco smoking have been accomplished with the 450K BeadChip, one using a small number of lymphoblasts and pulmonary macrophages of current and never smokers [12], another one using cord blood samples from newborns to study the effect of maternal smoking [16], and a very recent one that assessed the impact of current and former smoking on DNA methylation using whole blood samples from healthy individuals who subsequently developed breast or colon cancer and matched controls [17]. RESULTS AND DISCUSSION Illumina 450K Analysis: Genome-wide Effect of Tobacco Smoking on the Methylation Status To investigate the effect of tobacco smoking on DNA methylation, we performed a genome-wide DNA methylation analysis with the Illumina 450K BeadChip using DNA obtained from whole blood. The characteristics of the discovery (F4) and the replication (F3) panel are summarized in Table 1. Visual presentation of the genome-wide distribution of the significant, differentially-methylated CpG sites of current vs. never smokers in the discovery (F4; current N = 262, never N = 749) and replication (F3; current N = 236, never N = 232) panel are represented as Manhattan Plots in Figure 1a and 1b respectively. [Figure: Genome-wide effect of current and former tobacco smoking on DNA methylation displayed by Manhattan Plots.The continuous lines mark the 1E-07 significance thresholds, the lower line in Figure 1b marks the 5E-05. The significant CpG sites are color coded with the direction of the aberration in current/former smokers, using blue for hypomethylated and red for hypermethylated CpG sites. a) Current vs. never smokers of the F4 discovery panel; b) Current vs. never smokers of the F3 replication panel; c) Former vs. never smokers of the F4 discovery panel.] [Table: Characteristics of the study populations.] Depending upon the smoking status, we identified 972 CpG sites with differential methylation levels after conservative correction for multiple testing (p≤1E-07) throughout the genome in F4 (Table S1), of which 187 CpG sites could be replicated in F3 (p≤5E-5; Table S2). Table 2 displays all replicated CpG sites of current vs. never smokers with a methylation difference of more than 5% in both panels. In addition, a meta-analysis of the F4 and F3 data sets was performed, displayed by the corresponding p-value in Table 2 and Table S2. [Table: Genome-wide significant differentially-methylated CpG sites of current compared to never smokers.] Overall, genome-wide significant differentially-methylated CpG sites could be detected in each of the 22 autosomes with p-values ranging from 9.31E-08 to 2.54E-182, and with a percent of variance explained by smoking of 1.31 to 41.02 (Table S2). Among the CpG sites showing DNA methylation differences of more than 5%, a remarkable clustering of smoking dependent changes in methylation patterns could be identified on chromosome 2q37.1 and 5p15.3 (Figure 1a and Table 2). The most striking and significant CpG site, cg05575921 (current smokers; F4: –24.40%, p = 2.54E-182, explained variance = 41.02%; F3: –23.29%, p = 1.81E-64, explained variance = 39.69%), is located in the region of chromosome 5p15.3 within the AHRR gene (Table 2 and Figure S1a). The human AHRR (aryl hydrocarbon receptor (AHR) repressor) codes for an evolutionary conserved bHLH-PAS (basic helix-loop-helix/Per-AHR nuclear translocator (ARNT)-Sim) protein. This protein is part of the aryl hydrocarbon receptor (AHR) signaling cascade, which mediates dioxin toxicity, is involved in regulation of cell growth and differentiation [18], [19] and the modulation of the immune system [20]. Furthermore, evidence exists for AHR crosstalk with estrogen receptor (ER) signaling, thereby impacting cell proliferation and metabolism by P450 enzymes [21]. An overview of the AHRR gene structure is given in Figure S1a. Tobacco smoke is a remarkable source of polycyclic aromatic hydrocarbons (PAHs) that trigger the AHR signaling pathway [22]–[24], leading to several pathological effects in humans through AHR-dependent changes in gene expression [25]–[28]. AHRR is a known tumor suppressor, mediating detoxification of PAHs, which are the principle carcinogenic agents causing tobacco-related lung and other cancers [29]. Recently a differential methylation of CpG sites in smokers within the AHRR gene has been demonstrated in lymphoblasts and pulmonary macrophages by Monick et al. [12]. Our findings are also in line within another recent study of Joubert et al. carried out in cord blood of newborns in order to analyze epigenome-wide methylation in relation to maternal smoking during pregnancy. This study also found cg05575921 in AHRR to be the most statistically significant CpG site and showed that lower methylation was associated